Prior treatments influence immunotherapy response in advanced melanoma

Research led by scientists at UCLA Jonsson Comprehensive Cancer Center found that responses to a type of immunotherapy called PD-1 checkpoint blockade in patients with advanced melanoma depended on whether or not they had previously received another immunotherapy—CTLA-4 blockade—as well as other factors.

Leave A Comment

Your email address will not be published. Required fields are marked *